Rituximab-induced interstitial pneumonitis in patient with non-Hodgkin lymphoma: a clinical case
Rituximab is a chimeric monoclonal antibody against CD20+ lymphocytes used to treat non-Hodgkin lymphoma, hematological and autoimmune diseases rheumatoid arthritis, systemic lupus erythematosus, thrombocytopenic purpura, hemolytic anemia, multiple sclerosis. The safety of the drug is critical to t...
Main Authors: | Nikolai A. Ognerubov, Tatiana S. Antipova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ZAO "Consilium Medicum"
2022-08-01
|
Series: | Consilium Medicum |
Subjects: | |
Online Access: | https://consilium.orscience.ru/2075-1753/article/viewFile/109882/84125 |
Similar Items
-
Interstitial pneumonitis during rituximab-containing chemotherapy for primary central nervous system lymphomas: a case report and review of literature
by: Yuchen Wu, et al.
Published: (2018-01-01) -
Experience of using rituximab for recurrent non-Hodgkin lymphoma in elderly patients of the Orel region
by: R. A. Golubenko, et al.
Published: (2014-07-01) -
Experience of using rituximab for recurrent non-Hodgkin lymphoma in elderly patients of the Orel region
by: R. A. Golubenko, et al.
Published: (2014-07-01) -
MRI versus CT and PET/CT in the Preoperative Assessment of Hodgkin and Non-Hodgkin Lymphomas
by: Francesca Maccioni, et al.
Published: (2021-10-01) -
Enhanced pro-apoptotic activity of rituximab through IBTK silencing in non-Hodgkin lymphoma B-cells
by: Eleonora Vecchio, et al.
Published: (2024-02-01)